Skip to Content
Merck
All Photos(1)

Documents

SML1796

Sigma-Aldrich

Atazanavir

≥98% (HPLC)

Synonym(s):

1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate, BMS-232632

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C38H52N6O7
CAS Number:
198904-31-3
Molecular Weight:
704.86
MDL number:
MFCD08435966
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -41 to -49°, c = 0.1 in ethanol

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(N[C@@H](C(C)(C)C)C(N[C@H]([C@H](CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)O)CC3=CC=CC=C3)=O)OC

InChI

1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

InChI key

AXRYRYVKAWYZBR-GASGPIRDSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Atazanavir inhibits the cleavage of gag and gag-pol polyproteins in human immunodeficiency virus. It is absorbed and metabolized by cytochrome P450 present in the liver. It has minimal side effects and has no effect on insulin sensitivity and serum lipid profile.

Biochem/physiol Actions

Atazanavir is an antiviral HIV protease inhibitor.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Atazanavir
Croom KF, et al.
Drugs, 69(8), 1107-1140 (2009)
HIV protease inhibitors: a review of molecular selectivity and toxicity
Lv Z, et al.
HIV/AIDS (Auckland, N.Z.), 7, 95-95 (2015)
Daniel W Cole et al.
Experimental cell research, 382(1), 111386-111386 (2019-05-11)
Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by
Saif Ahmad Khan et al.
Pharmaceutics, 12(11) (2020-11-12)
Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of
Masayuki Amano et al.
Scientific reports, 7(1), 12235-12235 (2017-09-28)
We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-crown-tetrahydrofuranylurethane (Crwn-THF), a P2'-methoxybenzene, and a sulfonamide isostere, is highly active against laboratory and primary clinical HIV-1 isolates (EC
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service